Update on riboflavin and multiple sclerosis: a systematic review

Naghashpour, Mahshid and Jafarirad, Sima and Amani, Reza and Sarkaki, Alireza and Saedisomeolia, Ahmad (2017) Update on riboflavin and multiple sclerosis: a systematic review. Iranian Journal of Basic Medical Sciences, 20 (9). pp. 958-966.

[img]
Preview
Text
IJBMS_Volume 20_Issue 9_Pages 958-966.pdf

Download (1MB) | Preview
Official URL: http://ijbms.mums.ac.ir/article_9257.html

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Riboflavin plays an important role in myelin formation, and its deficiency is implicated as a risk factor for multiple sclerosis. Here, we systematically reviewed the literature concerning the health benefits of riboflavin on MS. The literature recorded within four main databases, including relevant clinical trials, experimental, and case-control studies from 1976 to 2017 were considered. Both human and animal studies were included for review, with no restrictions on age, gender, or ethnicity. Experimental studies demonstrated that riboflavin deficiency triggers neurologic abnormalities related to peripheral neuropathies such as demyelinating neuropathy. Moreover, randomized controlled trials (RCT) and case-control studies in which MS patients received riboflavin supplementation or had higher dietary riboflavin intake showed improvements in neurological motor disability. Riboflavin is a cofactor of xanthine oxidase and its deficiency exacerbates low uric acid caused by high copper levels, leading to myelin degeneration. The vitamin additionally plays a significant role in the normal functioning of glutathione reductase (GR) as an antioxidant enzyme, and conditions of riboflavin deficiency lead to oxidative damage. Riboflavin promotes the gene and protein levels of brain-derived neurotrophic factor (BDNF) in the CNS of an animal model of MS, suggesting that BDNF mediates the beneficial effect of riboflavin on neurological motor disability. Research to date generally supports the role of riboflavin in MS outcomes. However, further observational and interventional studies on human populations are warranted to validate the effects of riboflavin.

Item Type: Article
Subjects: QV pharmacology
Divisions: Journals > Iranian J Basic Medical Sciences
Depositing User: ijbms ijbms
Date Deposited: 02 Nov 2017 15:55
Last Modified: 02 Nov 2017 15:55
URI: http://eprints.mums.ac.ir/id/eprint/8474

Actions (login required)

View Item View Item